Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment

Hoth Therapeutics Inc. shares fell 5.16% as the stock crossed below its 5-day SMA amid broader market gains in the Nasdaq-100 and S&P 500.

The company's GDNF therapy, co-developed with the U.S. Veterans Administration, demonstrated superior efficacy compared to semaglutide in a preclinical study, showing significant weight loss and improved metabolic health in female models. Hoth plans to accelerate GDNF towards IND-enabling studies, targeting clinical trials in 2027, which could position it as a disruptive treatment in the $200 billion obesity market.

The promising results of GDNF highlight its potential to address the limitations of current GLP-1 agonists, suggesting a significant opportunity for Hoth in the healthcare landscape as it continues to advance its research and development efforts.